https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg00webadminhttps://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svgwebadmin2012-10-09 09:10:382026-09-21 14:00:39Astex Pharmaceuticals Earns $5 Million for First Commercial Sale of DACOGEN(R) in the European Union
https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg00webadminhttps://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svgwebadmin2012-09-28 09:17:202026-09-21 14:00:55DACOGEN(R) Approved in the European Union for the Treatment of Acute Myeloid Leukemia
https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg00webadminhttps://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svgwebadmin2012-09-21 09:19:502026-09-21 14:01:47Astex Pharmaceuticals Discontinues Amuvatinib Clinical Development Program
https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg00webadminhttps://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svgwebadmin2012-09-06 09:24:212026-09-21 14:02:01Astex Pharmaceuticals, Cancer Research Technology and The Institute of Cancer Research Announce Epigenetic Drug Discovery Collaboration
https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg00webadminhttps://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svgwebadmin2012-09-04 09:27:102026-09-21 14:02:06Astex Pharmaceuticals to Participate on Epigenetics Panel at Rodman & Renshaw Conference
https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg00webadminhttps://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svgwebadmin2012-08-20 09:29:142026-09-21 14:03:07Astex President Awarded Prous Institute-Overton and Meyer Award for New Technologies in Drug Discovery
https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg00webadminhttps://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svgwebadmin2012-07-24 09:33:082026-09-21 14:03:24Astex Pharmaceuticals to Announce 2012 Second Quarter Financial Results on July 30,
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
